½ÃÀ庸°í¼­
»óǰÄÚµå
1463640

Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå : ¿¹Ãø(-2030³â) Áö¿ª ºÐ¼® - Á¦Ç°º°, ¼ö¼úº°, ÃÖÁ¾ »ç¿ëÀÚº°

South & Central America Aortic Valve Replacement Devices Market Forecast to 2030 - Regional Analysis - by Product, Surgery, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 83 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº 2022³â 3¾ï 6,563¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 8¾ï 7,641¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 11.5%·Î ÃßÁ¤µË´Ï´Ù.

´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±âÀÇ Áøº¸°¡ Áß³²¹Ì ´ëµ¿¸Æ ÆÇ¸· ±³Ã¼ ÀåÄ¡ ½ÃÀåÀ» µÞ¹Þħ

°æ Ä«Å×ÅÍ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR)°ú °°Àº Àúħ½À ¼ö¼ú ÀýÂ÷(MIS)ÀÇ °³¹ßÀº ´ëµ¿¸Æ ÆÇ¸· ÇùÂøÁõ(AS)ÀÇ Ä¡·á¸¦ Çö´ëÈ­Çß½À´Ï´Ù. °æ Ä«Å×ÅÍ ´ëµ¿¸ÆÆÇ¸· ġȯ¼úÀº Á¾·¡ÀÇ °³½É¼úº¸´Ù ħ½ÀÀÌ Àû±â ¶§¹®¿¡ Áö±Ý±îÁö ¼ö¼úÀÇ ´ë»óÀÌ µÇÁö ¾Ê¾Ò´ø °íÀ§ÇèÀÇ È¯ÀÚ¿¡¼­µµ Ä¡·á¸¦ ¹Þ°Ô µÇ¾ú½À´Ï´Ù. °Ô´Ù°¡, Àç·á¿Í µðÀÚÀÎÀÇ °³¹ßÀº ´õ ưưÇÏ°í »ýüÀûÇÕ¼ºÀÌ ³ôÀº ´ëµ¿¸ÆÆÇ¸· ġȯ¼úÀ» °³¹ßÇÏ¿© ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ÇÕº´ÁõÀÇ À§ÇèÀ» °¨¼Ò½Ãŵ´Ï´Ù.

´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±âÀÇ ±â¾÷¿¡ ÀÇÇÑ ¸î °¡Áö ±â¼úÀû Áøº¸´Â ´ÙÀ½°ú °°½À´Ï´Ù.

2023³â 1¿ù, AbbottÀº °³½É¼ú À§ÇèÀÌ ³ôÀº ½É°¢ÇÑ ´ëµ¿¸Æ ÆÇ¸· ÇùÂøÁõ ȯÀÚ¸¦ Ä¡·áÇϱâ À§ÇÑ °æ Ä«Å×ÅÍ ´ëµ¿¸Æ ÆÇ¸· À¯Ä¡(TAVI) ½Ã½ºÅÛ '³ªºñÅç'ÀÇ FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. NavitolÀº AbbottÀÇ ±¤¹üÀ§ÇÑ °æ°æ Ä«Å×ÅÍ ±¸Á¶ ½ÉÀå Æ÷Æ®Æú¸®¿À¿¡ Âü°¡ÇÑ ÃֽŠÁ¦Ç°À¸·Î ÀÇ»ç¿Í ȯÀÚ¿¡°Ô ´Ù¾çÇÑ ½É°¢ÇÑ ½ÉÀå Áúȯ¿¡ ´ëÇÑ Ä§½ÀÀÌ ÀûÀº Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

2021³â 9¿ù, AbbotÀº ´ëµ¿¸Æ ÆÇ¸·°ú ½Â¸ðÆÇ Áúȯ ȯÀÚÀÇ Ä¡·á ¿É¼ÇÀ» °³¼±Çϱâ À§ÇØ Epic Plus ¹× Epic Plus Supra Stented Tissue ValvesÀÇ FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ »õ·Î¿î Àåºñ·Î ¾Öº¿Àº ¿¡ÇÈ ¼ö¼ú ¹ëºê Ç÷§ÆûÀ» È®ÀåÇß½À´Ï´Ù.

µû¶ó¼­ ±â¼úÀû Áøº¸´Â ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ ¸¸µé¾î ³Â½À´Ï´Ù.

Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå °³¿ä

Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª ¹× ±âŸ Áß³²¹Ì·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀåÀº ´ëµ¿¸Æ ÆÇ¸· ÇùÂøÁõÀÇ À¯º´·ü ±ÞÁõ, ÆÇ¸· ´ëü ¼ö¼ú¿¡ ´ëÇÑ ÀÎÁöµµ¸¦ ³ôÀ̱â À§ÇÑ ´Ù¾çÇÑ Á¤ºÎ Á¶Á÷ÀÇ ³ë·Â¿¡ ÀÇÇØ ¼ºÀåÀÌ Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù.

Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå ¼öÀͰú ¿¹Ãø(-2030³â)(±Ý¾×)

Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå ¼¼ºÐÈ­

Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº Á¦Ç°, ¼ö¼ú, ÃÖÁ¾ »ç¿ëÀÚ ¹× ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.

Á¦Ç°º°·Î Áß³²¹Ì ´ëµ¿¸Æ ¹ëºê ´ëü ÀåÄ¡ ½ÃÀåÀº ºÀÇÕµÇÁö ¾ÊÀº ¹ëºê¿Í ±â°è½Ä ¹ëºê·Î ºÐÇҵ˴ϴÙ. 2022³â Áß³²¹Ì ´ëµ¿¸ÆÆÇ ±³Ã¼ ÀåÄ¡ ½ÃÀåÀº ¹«ºÀÇÕ ¹ëºê°¡ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

¼ö¼ú¿¡ µû¶ó Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº ³·Àº ħ½À ¼ö¼ú°ú °³º¹ ¼ö¼ú·Î ³ª´¹´Ï´Ù. ³·Àº ħ½À ¼ö¼ú ºÎ¹®Àº 2022³â Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå¿¡¼­ ´õ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀ¸·Î ±¸ºÐµË´Ï´Ù. º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®Àº 2022³â Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå Á¡À¯À²¿¡¼­ Ãִ븦 Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î Áß³²¹Ì ´ëµ¿¸ÆÆÇ ±³Ã¼ ÀåÄ¡ ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª ¹× ±âŸ Áß³²¹Ì·Î ºÐ·ùµË´Ï´Ù. ºê¶óÁúÀº 2022³â Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå Á¡À¯À²À» µ¶Á¡Çß½À´Ï´Ù.

Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, LivaNova Plc, Edwards Lifesciences Corp, Braile Biomedica Industry, Commerce and Representations Ltd, Artivion Inc, Venus MedTech HangZhou Inc, Labcor Laboratorios Ltda. µîÀÌ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ´ë±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå »óȲ

  • °³°ü
  • PEST ºÐ¼®
    • Áß³²¹Ì PEST ºÐ¼®

Á¦5Àå Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå : ÁÖ¿ä »ê¾÷¿ªÇÐ

  • ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ´ëµ¿¸ÆÆÇ ġȯ ¼ö¼ú °Ç¼ö Áõ°¡
    • ³·Àº ħ½À ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Á¦Ç° ¸®ÄÝ
    • ½ÉÀ屸Á¶ÀåÄ¡¿¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦
  • ½ÃÀå ±âȸ
    • ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±âÀÇ Áøº¸
  • ÇâÈÄÀÇ µ¿Çâ
    • ÀÓ»ó ¿¬±¸ Áõ°¡
  • ¿µÇ⠺м®

Á¦6Àå ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå : Áß³²¹Ì ½ÃÀå ºÐ¼®

  • Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå ¼öÀÍ(2022³â-2030³â)

Á¦7Àå ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå - ¼öÀͰú ¿¹Ãø(-2030³â) : Á¦Ç°º°

  • Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå : Á¦Ç°º° ¼öÀÍ Á¡À¯À²(%)(2022³â, 2030³â)
  • ¸ÞÄ«´ÏÄà ¹ëºê
  • ¹«ºÀÇÕ¹ëºê

Á¦8Àå Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå - ¼öÀͰú ¿¹Ãø(-2030³â) : ¼ö¼úº°

  • Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå : ¼ö¼úº° ¼öÀÍ Á¡À¯À²(%)(2022³â, 2030³â)
  • °³º¹ ¼ö¼ú
  • Àúħ½À ¼ö¼ú

Á¦9Àå Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå - ¼öÀͰú ¿¹Ãø(-2030³â) : ÃÖÁ¾ »ç¿ëÀÚº°

  • Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº° ¼öÀÍ Á¡À¯À²(%)(2022³â, 2030³â)
  • º´¿ø ¹× Áø·á¼Ò
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦10Àå Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå : ±¹°¡º° ºÐ¼®

  • ºê¶óÁú
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ Áß³²¹Ì

Á¦11Àå ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå : ¾÷°è Á¤¼¼

  • Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå¿¡¼­ÀÇ ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«

Á¦12Àå ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Abbott Laboratories
  • Medtronic Plc
  • Boston Scientific Corp
  • LivaNova Plc
  • Edwards Lifesciences Corp
  • Braile Biomedica Industry, Commerce and Representations Ltd
  • Artivion Inc
  • Venus MedTech HangZhou Inc
  • Labcor Laboratorios Ltda.

Á¦13Àå ºÎ·Ï

BJH 24.05.23

The South & Central America aortic valve replacement devices market is expected to grow from US$ 365.63 million in 2022 to US$ 876.41 million by 2030. It is estimated to grow at a CAGR of 11.5% from 2022 to 2030.

Advancements in Aortic Valve Replacement Devices Fuels South & Central America Aortic Valve Replacement Devices Market

The development of minimally invasive surgical techniques (MIS), such as transcatheter aortic valve replacement (TAVR), has modernized the treatment of aortic stenosis (AS). Transcatheter aortic valve replacement is less invasive than traditional open-heart surgery, making it possible for high-risk patients who may not have been eligible for surgery to receive treatment. Moreover, developments in materials and design have led to the development of stronger and biocompatible aortic valve replacements, which have improved patient outcomes and reduced the risk of complications.

A few technological advancements by the players in the aortic valve replacement devices are mentioned below:

In January 2023, Abbott received FDA approval for the Navitor transcatheter aortic valve implantation (TAVI) system to treat people with severe aortic stenosis at high risk of open-heart surgery. Navitor is the latest addition to the company's extensive transcatheter structural heart portfolio, which offers physicians and patients less invasive treatment options for a range of serious heart diseases.

In September 2021, Abbott received FDA approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. With this new device, Abbott expanded its Epic surgical valve platform.

Therefore, technological advancements are creating lucrative opportunities in the aortic valve replacement devices market.

South & Central America Aortic Valve Replacement Devices Market Overview

The South & Central America aortic valve replacement devices market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in the region is expected to grow due to the surge in prevalence of aortic stenosis, initiatives undertaken by various government organizations to create awareness about valve replacement surgeries.

South & Central America Aortic Valve Replacement Devices Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Aortic Valve Replacement Devices Market Segmentation

The South & Central America aortic valve replacement devices market is segmented into product, surgery, end user, and country.

Based on product, the South & Central America aortic valve replacement devices market is segmented into sutureless valve and mechanical valve. The sutureless valve held a larger South & Central America aortic valve replacement devices market share in 2022.

Based on surgery, the South & Central America aortic valve replacement devices market is segmented into minimally invasive surgery and open surgery. The minimally invasive surgery segment held a larger South & Central America aortic valve replacement devices market share in 2022.

Based on end user, the South & Central America aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment held the largest South & Central America aortic valve replacement devices market share in 2022.

Based on country, the South & Central America aortic valve replacement devices market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America aortic valve replacement devices market share in 2022.

Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, LivaNova Plc, Edwards Lifesciences Corp, Braile Biomedica Industry, Commerce and Representations Ltd, Artivion Inc, Venus MedTech HangZhou Inc, and Labcor Laboratorios Ltda. , are some of the leading companies operating in the aortic valve replacement devices market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. South & Central America Aortic Valve Replacement Devices Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 South & Central America PEST Analysis

5. South & Central America Aortic Valve Replacement Devices Market - Key Industry Dynamics

  • 5.1 Key Market Drivers:
    • 5.1.1 Rising Number of Aortic Valve Replacement Surgeries
    • 5.1.2 Increasing Demand for Minimally Invasive Techniques
  • 5.2 Market Restraints
    • 5.2.1 Product Recalls
    • 5.2.2 Stringent Regulations Regarding Structure Heart Devices
  • 5.3 Market Opportunities
    • 5.3.1 Advancements in Aortic Valve Replacement Devices
  • 5.4 Future Trends
    • 5.4.1 Increasing Number of Clinical Studies
  • 5.5 Impact Analysis:

6. Aortic Valve Replacement Devices Market - South & Central America Market Analysis

  • 6.1 South & Central America Aortic Valve Replacement Devices Market Revenue (US$ Mn), 2022 - 2030

7. South & Central America Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 - by Product

  • 7.1 Overview
  • 7.2 South & Central America Aortic Valve Replacement Devices Market Revenue Share, by Product 2022 & 2030 (%)
  • 7.3 Mechanical Valve
    • 7.3.1 Overview
    • 7.3.2 Mechanical Valve: South & Central America Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Sutureless Valve
    • 7.4.1 Overview
    • 7.4.2 Sutureless Valve: South & Central America Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 (US$ Million)

8. South & Central America Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 - by Surgery.

  • 8.1 Overview
  • 8.2 South & Central America Aortic Valve Replacement Devices Market Revenue Share, by Surgery, 2022 & 2030 (%)
  • 8.3 Open Surgery
    • 8.3.1 Overview
    • 8.3.2 Open Surgery: South & Central America Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Minimally Invasive Surgery
    • 8.4.1 Overview
    • 8.4.2 Minimally Invasive Surgery: South & Central America Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 (US$ Million)

9. South & Central America Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 - by End User.

  • 9.1 Overview
  • 9.2 South & Central America Aortic Valve Replacement Devices Market Revenue Share, by End User, 2022 & 2030 (%)
  • 9.3 Hospitals & Clinics
    • 9.3.1 Overview
    • 9.3.2 Hospitals & Clinics: South & Central America Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Ambulatory Surgery Centers
    • 9.4.1 Overview
    • 9.4.2 Ambulatory Surgery Centers: South & Central America Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Others
    • 9.5.1 Overview
    • 9.5.2 Others: South & Central America Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 (US$ Million)

10. South & Central America Aortic Valve Replacement Devices Market - Country Analysis

  • 10.1 South & Central America Aortic Valve Replacement Devices Market, Revenue and Forecast to 2030
    • 10.1.1 Overview
    • 10.1.2 South & Central America Aortic Valve Replacement Devices Market by Country
      • 10.1.2.1 Brazil
        • 10.1.2.1.1 Overview
        • 10.1.2.1.2 Brazil Aortic Valve Replacement Devices Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.2.1.3 Brazil Aortic Valve Replacement Devices Market, by Product
        • 10.1.2.1.4 Brazil Aortic Valve Replacement Devices Market, by Surgery
        • 10.1.2.1.5 Brazil Aortic Valve Replacement Devices Market, by End-User
      • 10.1.2.2 Argentina
        • 10.1.2.2.1 Overview
        • 10.1.2.2.2 Argentina Aortic Valve Replacement Devices Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.2.2.3 Argentina Aortic Valve Replacement Devices Market, by Product
        • 10.1.2.2.4 Argentina Aortic Valve Replacement Devices Market, by Surgery
        • 10.1.2.2.5 Argentina Aortic Valve Replacement Devices Market, by End-User
      • 10.1.2.3 Rest of South & Central America
        • 10.1.2.3.1 Overview
        • 10.1.2.3.2 Rest of South & Central America Aortic Valve Replacement Devices Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.2.3.3 Rest of South & Central America Aortic Valve Replacement Devices Market, by Product
        • 10.1.2.3.4 Rest of South & Central America Aortic Valve Replacement Devices Market, by Surgery
        • 10.1.2.3.5 Rest of South & Central America Aortic Valve Replacement Devices Market, by End-User

11. Global Aortic Valve Replacement Devices Market Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in South & Central America Aortic Valve Replacement Devices Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Key Company Profiles

  • 12.1 Abbott Laboratories
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Medtronic Plc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Boston Scientific Corp
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 LivaNova Plc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Edwards Lifesciences Corp
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Braile Biomedica Industry, Commerce and Representations Ltd
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Artivion Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Venus MedTech HangZhou Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Labcor Laboratorios Ltda.
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦